Objective:

To inform about the FDA approval of an every-8-week maintenance dosing regimen for lebrikizumab in treating moderate-to-severe atopic dermatitis.

Approach:

Key Findings:

• No new safety signals were identified in the 32-week ADjoin every-8-week extension.
• No patients discontinued treatment due to adverse events through 32 weeks.
• Common adverse reactions included conjunctivitis, injection-site reactions, and herpes zoster.

Interpretation:

Lebrikizumab is a monoclonal antibody targeting interleukin-13, approved for patients whose disease is not adequately controlled with topical therapies.

Limitations:

• The safety profile is based on data from the ADjoin trial and may not encompass all patient populations.

Conclusion:

The option for every-8-week maintenance dosing represents a significant development for patients with moderate-to-severe atopic dermatitis.

Sources:

• Eli Lilly and Company
Source

Based on findings from:

FDA Approves Less Frequent Lebrikizumab Dosing

Kathryn Wighton. MDSpire News, 2026.

https://news.mdspire.com/dermatology/articles/fda-approves-less-frequent-lebrikizumab-dosing/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.